|
|
|
|
|
|
|
|
SGO conference
Monday, March 21, 2016 03:13 PM - 03:20 PM
•All arms have excessive toxicity
•Neurotoxicity is similarly high in all arms
•Reserve changes in treatment recommendations until survival data available for no residual disease high grade serous Stage III participants.
•IP Cisplatin increases bevacizumab associated HTN (hypertension)
•Survival for optimal and no residual disease participants will not be available for a few years.
•Dose reductions of paclitaxel and cisplatin as well as cross-over may have compromised efficacy.
•Dose dense paclitaxel may have improved efficacy to allow us to abandon IP chemo-must we wait-combine both?
•Bevacizumab interactions could have clouded analysis
Results: Among, 1,560 trial participants, the median age was 58 years. 84% had Stage III disease, 72% had high grade serous histology, 57% had no visible residual disease following optimal cytoreduction. Completion rates of platinum, taxane, or bevacizumab appear in the Table. Cross-over to the IV only therapy occurred in 16% randomized to IP carbo arm and 28% randomized to IP cis arm.
Treatment Arm |
At least 6 cycles of Platinum
|
At least 6 cycles of Taxane
|
Median # bev cycles
|
IV only |
90%
|
87%
|
20
|
IP carbo |
91%
|
88%
|
18
|
IP cis |
84%
|
87%
|
17
|
Conclusions: The progression free survival was not improved with IP chemotherapy. IV and IP carbo arms using weekly dose-dense paclitaxel were better tolerated than the IP cis arm. Neurotoxicity is a major problem on all arms. The reduced dose IP cisplatin regimen does not appear to be as effective as previously reported high dose cisplatin regimens. Survival data is not yet mature.
- Powerpoint Upload - SGO GOG 252 3-7-2016JM.ppt
- PDF Upload - Walker A PHASE III CLINICAL TRIAL OF BEVACIZUMAB.pdf
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.